Shares of Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $41.25, but opened at $43.64. Disc Medicine shares last traded at $42.88, with a volume of 48,915 shares trading hands.
Analyst Upgrades and Downgrades
IRON has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $57.00 target price (up from $43.00) on shares of Disc Medicine in a research note on Friday, June 14th. Raymond James raised their target price on shares of Disc Medicine from $40.00 to $43.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. BMO Capital Markets restated an “outperform” rating and issued a $70.00 target price (up from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. Morgan Stanley lowered their target price on shares of Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Disc Medicine in a research note on Friday, June 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus target price of $62.57.
View Our Latest Report on IRON
Disc Medicine Stock Up 7.1 %
Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). As a group, analysts expect that Disc Medicine, Inc. will post -4.56 earnings per share for the current year.
Insider Activity at Disc Medicine
In related news, Director William Richard White sold 2,560 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $31.80, for a total transaction of $81,408.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.24% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRON. Strs Ohio increased its holdings in Disc Medicine by 66.7% in the fourth quarter. Strs Ohio now owns 1,000 shares of the company’s stock valued at $57,000 after buying an additional 400 shares in the last quarter. AJOVista LLC purchased a new position in Disc Medicine in the fourth quarter valued at $63,000. China Universal Asset Management Co. Ltd. purchased a new position in Disc Medicine in the fourth quarter valued at $161,000. ProShare Advisors LLC purchased a new position in Disc Medicine in the first quarter valued at $211,000. Finally, Bleakley Financial Group LLC purchased a new position in Disc Medicine in the fourth quarter valued at $215,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.
Disc Medicine Company Profile
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Further Reading
- Five stocks we like better than Disc Medicine
- How to Invest in Insurance Companies: A Guide
- McDonald’s Stock: Balancing Value and Innovation
- CD Calculator: Certificate of Deposit Calculator
- MarketBeat Week in Review – 6/17 – 6/21
- Health Care Stocks Explained: Why You Might Want to Invest
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.